Aptinyx (APTX) Appoints Gilmore O’Neill to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
Aptinyx Appoints Gilmore O’Neill, M.B., M.M.Sc., to Board of Directors
October 20, 2021 7:57 AM EDTEVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore ONeill, M.B., M.M.Sc., to the companys board of directors. Dr. ONeill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics.
Gilmore brings an exceptional background of experience and leadership to the Aptinyx board of directors, said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. His expertise in research and clinical... More
